Arizona Glaucoma Specialists

DocTrials

Glaucoma

Ocular Hypertension

Hypertension

Open-Angle Glaucoma

Bimatoprost

Timolol Maleate

DE-126

Latanoprost

Netarsudil

DE-117

AbbVie

Santen

Aerie Pharmaceuticals

Allergan

Mati Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

DocTrials | Arizona Glaucoma Specialists

Site insights

Work at this site?

Active trials

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

Trial sponsors